Pharmacists play key role in diabetes care evolution

Due to the wide array of available treatments, pharmacists play a crucial role in screening, diagnosis, and education to effectively manage migraine medications. Amaal Starling, MD, FAHS, FAAN, shared insights on this and more. #NCPA2025 Read More: https://hubs.li/Q03PdSdG0

Across towns and neighborhoods, community pharmacists are stepping up in unexpected ways—leading efforts to close longstanding gaps in migraine care. According to recent coverage, pharmacists at the local level are offering screening, managing medication plans, and proactively engaging with patients who might otherwise fall through the cracks. Their role stretches far beyond the counter. When pharmacists recognize the early signs of migraine, provide counseling on treatment options, and coordinate care alongside neurologists, they become the key connection between patients and better outcomes. In a field where specialists are scarce, these accessible professionals can make a meaningful difference. The takeaway is clear: when pharmacists lead with insight and initiative, patient care elevates. Their work doesn’t just relieve pain—it empowers people to live fuller lives. Let’s celebrate the evolving role of pharmacy, where each conversation and intervention transforms what “local care” can mean. Read more. Drug Topics https://ow.ly/uXen50XeIPw #RxSpeaks #PharmacyLeadership #CommunityCare #MigraineManagement

"The GLP-1 story is emblematic of a bigger shift in healthcare: the move from drug-centric to system-centric medicine. These medications don’t just test the limits of what pharmacology can do; they test how well healthcare systems can adapt. The GLP-1 story is emblematic of a bigger shift in healthcare: the move from drug-centric to system-centric medicine. These medications don’t just test the limits of what pharmacology can do; they test how well healthcare systems can adapt. For now, pharmacists are the connective tissue holding that adaptation together. They troubleshoot insurance denials, educate patients, prevent medication-related complications, and flag early signs of nonadherence. Their expertise complements that of physicians and nurses, extending the reach of the care team into the moments between office visits — where most adherence failures and adverse events occur. While reimbursement models and staffing constraints still limit how widely these roles can be implemented, pharmacist-led interventions have been linked to better medication adherence, fewer hospitalizations, and stronger chronic disease control." https://lnkd.in/eayiES4g

Study casts doubt on polypharmacy policies but notes value of GP-pharmacist link-up An NHS-backed trial has found that enhanced medication reviews for patients prescribed multiple medicines do not improve prescribing safety, casting doubt on the effectiveness of current health service strategies to tackle polypharmacy. Lead author Professor Rupert Payne, senior academic GP at the University of Exeter, said: 'It adds strong evidence that the strategies being used by the NHS to improve medicines safety need to be reconsidered.' #polypharmacy #medicines #GPs #pharmacists #pharmacy #UKpharmacy #prescribing

🚨 Emergency Medications – LinkedIn A Quick Reference for Healthcare Professionals 💉 In emergency and critical care situations, every second matters. Knowing the right medication, correct indication, and accurate dosage can make a life-saving difference. Here's a concise yet powerful reference for some of the most commonly used emergency drugs: ❤️ ●Adenosine (6 mg IV push) – Used in supraventricular tachycardia (SVT) to restore normal sinus rhythm. ⚡ ●Amiodarone (300 mg IV) – For ventricular arrhythmias; an essential antiarrhythmic in cardiac arrest protocols. 💧 ●Dopamine (2–20 mcg/kg/min IV infusion) – Used for bradycardia and hypotension to support cardiac output and blood pressure. ❤️🔥 ●Epinephrine (1 mg IV every 3–5 min) – A life-saving drug in cardiac arrest, helping to stimulate heart activity and improve perfusion. 🫁 ●Furosemide (40 mg IV) – For pulmonary edema, reduces fluid overload and improves breathing effort. 🧠 ●Lorazepam (4 mg IV) – Used in status epilepticus to control prolonged seizure activity. ⚙️ Magnesium sulfate (1–2 g IV) – Effective in torsades de pointes and certain cases of severe eclampsia. 🩹 ●Naloxone (0.4 mg IV) – An opioid antagonist that reverses opioid overdose and restores respiratory function. 💔 ●Nitroglycerin (0.4 mg SL) – For chest pain and acute coronary syndrome (ACS), promotes vasodilation and relieves cardiac workload. 🧑⚕️ ●As healthcare providers, continuous learning and staying prepared for emergencies is essential. These are medications we rely on every day to stabilize and save lives. #Nursing #CriticalCare #EmergencyMedicine #HealthcareProfessionals #NurseEducation #MedicationSafety #PatientCare #ClinicalSkills #RapidResponse AIIMS (All India Institute of Medical Sciences, New Delhi) Cipla Sunpharma Prohance Dallah Hospital Apollo Hospitals MANKIND PHARMA LTD Emcure Pharmaceuticals Limited BioMarin Pharmaceutical Inc. Himanshu Loyal

The White House announced today that the prescription medications, Wegovy and Zepbound, used for chronic weight management, will now be covered by Medicare-covered patients for a co-pay of $50 per month. Ozempic (indicated for Type 2 Diabetes) and Wegovy (indicated for chronic weight management) will now cost $350 per month when purchased through TrumpRx. Zepbound (indicated for chronic weight management) will now cost an average of $346 per month. Orforglipron, Eli Lilly's highly anticipated oral GLP-1RA medication that will likely apply for FDA approval by the end of the year, would also be priced the same (if approved). Improved patient access to highly effective obesity and diabetes treatment should always be applauded, but remember that medication is only one component of comprehensive obesity care and should be monitored by an experienced obesity care provider. The Obesity Society

Big news: Desiree Priestley's byline is live in MedCity News. Prescription digital therapeutics (PDTs) are at an inflection point. With FDA rigor, payer interest, and growing patient demand for convenience and personalization, PDTs are reshaping how mental healthcare is delivered and experienced. From access gaps to alternatives beyond medication, Desiree shares what’s possible when healthcare meets people where they are. Read the full article here: https://lnkd.in/gKqNH38Z #DigitalTherapeutics #MentalHealthInnovation #HealthExperience #Rejoyn

In a recent Medscape article, Thomas So, PharmD, MBA-HCA, senior manager of the Consumer Drug Information Group at FDB, sharesFDB, shares a valuable perspective on the growing challenges surrounding GLP-1 therapies — from patient access and affordability to the impact on health systems and care coordination.   Dr. So discusses how pharmacists are at the center of this evolving landscape, helping patients navigate barriers while ensuring safe, effective use of these complex medications. His insights underscore how better data, clinical context, and communication across care teams can improve adherence and outcomes. The piece, written by Kristin Jenkins, offers an important look at the real-world pressures shaping this moment in pharmacy and patient care. Read it here: https://wb.md/43oAnj1 | #MedAdherence

Big news! This decision expands access to renal denervation to many more patients throughout the United States. Recor Medical and Medtronic both gained FDA approval for their RDN systems in 2023, and other vendors are actively developing their own treatment options.

The decision by CMS to provide Medicare coverage for the use of renal denervation (RDN) is a huge win for hypertensive patients, their healthcare providers, and the MedTech industry.